Crossmark

Safety and efficacy of obinutuzumab in Chinese patients with B‐cell lymphomas: a secondary analysis of the GERSHWIN trial

Crossref DOI link: https://doi.org/10.1186/s40880-018-0300-5

Published Online: 2018-05-30

Published Print: 2018-12

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Qin, Yan

Song, Yuqin

Shen, Zhixiang

Du, Xin

Ji, Wei

Hsu, Wanling

Zhu, Jun

Shi, Yuankai
Funding

Funding for this research was provided by:

F. Hoffmann-La Roche Ltd.
License Information

Version of Record valid from 2018-05-30
More Information

Publication History

Received: 2017-10-23

Accepted: 2018-03-28

Published: 2018-05-30